Cargando…

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histone deacetylase inhibitor that differs from approved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribrag, Vincent, Kim, Won Seog, Bouabdallah, Reda, Lim, Soon Thye, Coiffier, Bertrand, Illes, Arpad, Lemieux, Bernard, Dyer, Martin J. S., Offner, Fritz, Felloussi, Zakia, Kloos, Ioana, Luan, Ying, Vezan, Remus, Graef, Thorsten, Morschhauser, Franck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477609/ https://www.ncbi.nlm.nih.gov/pubmed/28126962 http://dx.doi.org/10.3324/haematol.2016.154377

Ejemplares similares

A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors
por: Deutsch, Eric, et al.
Publicado: (2016)

Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms
por: Ali, A, et al.
Publicado: (2013)

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat
por: Rivera, Sofia, et al.
Publicado: (2017)

Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts
por: Gressette, Mélanie, et al.
Publicado: (2014)

Open Questions in the Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma
por: Tyran, Marguerite, et al.
Publicado: (2014)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Effect of Bleomycin Hydrolase Gene Polymorphism on Late Pulmonary Complications of Treatment for Hodgkin Lymphoma
por: Jóna, Ádám, et al.
Publicado: (2016)

Late Effect of the Cervical Irradiation on Periodontal Status and Cariogen Flora in Hodgkin Lymphoma Patients
por: Simon, Zsófia, et al.
Publicado: (2011)

Rapidly Progressing Refractory Hodgkin Lymphoma: A Case Report and a Possible Explanation
por: Jóna, Ádám, et al.
Publicado: (2016)

Employment status and health related quality of life among Hodgkin-lymphoma survivors’– results based on data from a major treatment center in Hungary
por: Magyari, Ferenc, et al.
Publicado: (2017)

Pulmonary Toxicity of Hodgkin Lymphoma Treatment: A Prospective Single-Center Study
por: Jona, Adam, et al.
Publicado: (2021)

Changing Patterns in the Clinical Pathological Features of Hodgkin Lymphoma: A Report from Debrecen, Hungary
por: Miltényi, Zsófia, et al.
Publicado: (2011)

Assessment of cognitive function in long-term Hodgkin lymphoma survivors, results based on data from a major treatment center in Hungary
por: Magyari, Ferenc, et al.
Publicado: (2022)

Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis
por: Hess, Georg, et al.
Publicado: (2015)

Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
por: Pinczés, László Imre, et al.
Publicado: (2020)

Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary
por: Husi, Kata, et al.
Publicado: (2023)

Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes
por: Matolay, Orsolya, et al.
Publicado: (2019)

Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma– Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma
por: Simon, Zsófia, et al.
Publicado: (2021)

P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)
por: Hodson, Daniel, et al.
Publicado: (2023)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial
por: Pettengell, Ruth, et al.
Publicado: (2018)

P069: Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients
por: Chuzel, Chloé, et al.
Publicado: (2022)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study
por: Busson, Raphaël, et al.
Publicado: (2019)

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
por: Warzocha, K., et al.
Publicado: (1998)

Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors
por: Torres-Collado, Antoni Xavier, et al.
Publicado: (2018)

Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation.
por: Xerri, L., et al.
Publicado: (1998)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
por: Zelenetz, Andrew D., et al.
Publicado: (2017)

Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies
por: Szász, Róbert, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Prognostic Significance of New Immunohistochemical Markers in Refractory Classical Hodgkin Lymphoma: A Study of 59 Cases
por: Canioni, Danielle, et al.
Publicado: (2009)

Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT
por: Rossi, Cédric, et al.
Publicado: (2017)

Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
por: Manson, Guillaume, et al.
Publicado: (2020)

Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
por: Decruyenaere, Philippe, et al.
Publicado: (2021)

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial
por: Montillo, Marco, et al.
Publicado: (2019)

Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy
por: Yoshimitsu, Makoto, et al.
Publicado: (2022)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
por: Castagna, Luca, et al.
Publicado: (2020)

A Case of Therapy-related Acute Myeloid Leukemia Following Treatment with 5-Fluorouracil
por: Pinczés, László, et al.
Publicado: (2018)

P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Kalac, Matko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i290bl37kcpojfno37dnnlkcrg